Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Corticorelin (Acthrel) vs Rezafungin (Rezzayo)
An educational, source-based comparison of Corticorelin (Acthrel) and Rezafungin (Rezzayo) — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic ovine CRH for differential diagnosis of Cushing's syndrome.
Synthetic ovine corticotropin-releasing hormone (oCRH) that stimulates pituitary ACTH release; used in inferior petrosal sinus sampling and peripheral CRH stimulation testing to distinguish pituitary from ectopic ACTH-dependent Cushing's syndrome.
- Differential diagnosis of ACTH-dependent Cushing's syndrome
- • FDA-approved.
- • Transient flushing, dyspnea, hypotension possible.
Once-weekly echinocandin for candidemia and invasive candidiasis.
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
- Candidemia
- Invasive candidiasis
- • FDA-approved (2023).
- • Infusion reactions and photosensitivity reported.
Corticorelin (Acthrel) vs Rezafungin (Rezzayo) — Key differences
- Class: Corticorelin (Acthrel) is classified as CRH Analog · Diagnostics, while Rezafungin (Rezzayo) is Echinocandin · Antifungal.
- Primary research focus: Corticorelin (Acthrel) — differential diagnosis of acth-dependent cushing's syndrome; Rezafungin (Rezzayo) — candidemia.
- Tag: FDA-Approved · Diagnostics vs FDA-Approved · Antifungal.